OraLiva, Inc. has been awarded a prestigious Direct to Phase II SBIR grant from the National Institute of Dental and Craniofacial Research (NIDCR) at the National Institutes of Health (NIH). This funding supports the continued development of our groundbreaking AI-linked cytomics-on-a-chip platform.
The project is designed to enable near-real-time identification and management of oral lichenoid lesions within primary care settings—bringing lab-level diagnostic accuracy directly to the dental chair.
Why this matters
Oral lichenoid lesions can be challenging to diagnose early, often requiring referral to specialists. By providing dental providers with a fast, non-invasive, and highly accurate solution, OraLiva’s platform has the potential to:
- Improve patient outcomes: enable earlier intervention and reduce the risk of late-stage complications.
- Support providers: give clinicians actionable data at the point of care.
- Lower costs: minimize the financial and health burden associated with delayed diagnoses.
Looking ahead
This NIH award represents both a recognition of OraLiva’s scientific progress and a major step toward transforming how oral health conditions are identified and managed. Our mission is to make advanced diagnostics more accessible and more effective for providers and patients alike.
